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After publication of this work [1], the authors became
aware of some errors in the figures with respect to the load-
ing controls for the western blots in Figure Two panel
A (Figure 1 here), Figure Five panel B (Figure 2 here)
and Figure Six panel A (Figure 3 here). These errors were
due to genuine mistakes in generating the figures from
templates and incorrect cropping of the western blot X-ray
film images. These errors had no impact on the scientific
conclusions of the article. The experiments reported in
these figures have been repeated and new images produced.* Correspondence: eastwood@wmin.ac.uk
1School of Life Sciences, University of Westminster, London, UK
Full list of author information is available at the end of the article
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unless otherwise stated.Figure Two panel A (Figure 1 here) - Experiment
assessing the influence of blocking thrombospopndin- 1
on normal and scleroderma fibroblasts in 3-dimensional
collagen gels was performed and western blot for
loading control GAPDH as well as total ERK and
phospho-ERK were completed.
Figure Five panel B (Figure 2 here) - Role of PDGF,
IFNb and TFGb and the influence of the kinase inhibitor
Gleevac on MAPK activation by normal fibroblasts was
carried out and the levels of total ERK and phospho-
ERK assessed.ptide reduces ERK phosphorylation in control and systemic
SP1 blocking peptide LSKL (AnaSpec), fibroblast lysates were prepared
ERK and phospho-ERK (both from Cell Signalling) and GAPDH (Abcam)
RK in SSc fibroblasts.
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Figure 2 Thrombospondin 1 (TSP1) contributes to platelet-derived growth factor (PDGF) and transforming growth factor (TGF)b
induced contractile activation in normal fibroblasts via the ERK signalling pathways. Normal fibroblasts were treated in collagen gels
with or without PDGF(P), TGFb or INFb (IFN), and in the presence of PDGF and the PDGF receptor inhibitor Gleevac (Gle), or combined TGFb and
INFb. Following gel contraction samples were analysed by western blotting for expression of total ERK and phospho-ERK compared to control
untreated cells (C). PDGF and TGFb induced the levels of phospho-ERK, which were inhibited in the presence of Gleevac and IFNb respectively.
Figure 3 The overexpression of thrombospondin 1 (TSP1) in systemic sclerosis (SSc) fibroblasts is dependent on endogenous
activation of ERK. Normal and SSc fibroblasts were treated with U0126 (ERK inhibitor) and interferon (IFN)b overnight, prior to determining
protein expression by western blotting using an anti-TSP1 antibody (Abcam). U0126 and IFN inhibited the over expression of TSP1 protein in
SSc fibroblasts.
Chen et al. Fibrogenesis & Tissue Repair  (2015) 8:4 Page 2 of 2Figure Six panel B (Figure 3 here) - The effect of the
ERK inhibitor (U0126) and IFNb on the expression of
thrombospondin-1 compared to the loading control
(GAPDH) was re-examined in normal and scleroderma
fibroblasts.
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